The Biologics Testing Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The biologics testing market has seen swift expansion in the recent past. The market which was valued at $5.92 billion in 2024 is projected to reach $6.85 billion in 2025, growing at a compound annual growth rate (CAGR) of 15.7%.
The Biologics Testing Global Market Report 2025 forecasts that by 2029, the market is expected to grow to a size of $12.91 billion with a compound annual growth rate (CAGR) of 17.2%.
Download Your Free Sample of the 2025 Biologics Testing Market Report and Uncover Key Trends Now!The key drivers in the biologics testing market are:
• Emergence of advanced therapies
• Increasing demand for contract testing services
• Expansion of biologics pipelines
• Globalization of biopharmaceutical manufacturing
The biologics testing market covered in this report is segmented –
1) By Product: Reagents And Kits, Instruments, Other Products
2) By Test Type: Endotoxin Test, Sterility Test, Mycoplasma Tests, Bioburden Tests, Residual Host-Cell Proteins And DNA Detection Tests, Virus Safety Test, Other Test Types
3) By Application: Vaccine Development And Manufacturing, Monoclonal Antibodies Development And Manufacturing, Cellular And Gene Therapy Products Development And Manufacturing, Blood And Blood Products Development And Manufacturing, Other Applications
The key trends in the biologics testing market are:
• The emergence of advanced therapies is influencing the future of the biologics testing market.
• There is an increasing demand for contract testing services shaping market trends.
• The expansion of biologics pipelines is a major trend for future growth.
• Globalization of biopharmaceutical manufacturing and demand for rapid testing solutions are trending in the industry.
The major players in the biologics testing market are:
• Charles River Laboratories Inc
North America was the largest region in the biologics testing market in 2024